Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06417762 · ClinicalTrials.gov registry record · NA
Dime La VerDAD: Verify, Debunk, and Disseminate
A NA study of COVID-19 and Influenza, sponsored by University of Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 1,400
- Enrollment target
- 4
- Study locations
NCT06417762 is a NA study of COVID-19 and Influenza that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 1,400 participants, below the 55,208-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The trial reports 4 study locations across 3 states.
The verdict
NCT06417762, a NA study of COVID-19 and Influenza, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 1,400 participants
- Enrollment target
- 4
- Study locations
Study Summary
Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity and mortality due to respiratory virus infections. Dime La Verdad is an innovative social media capacity-building program based on theoretical frameworks related to health communication that empowers community health workers to disseminate reliable information about respiratory virus protection strategies through the use of personal narratives on social media. The proposed work will use a rigorous stepped wedge design to 1) deliver a scalable program of science communicators using an adapted curriculum grounded in principles of health communication, 2) evaluate how diffusion of health messaging is perceived on social media, and 3) discern how use of personal narratives to enhance science communication can encourage informed decision-making to promote evidence-based immunization practices and improve health outcomes.
Conditions Studied
Interventions
- BEHAVIORAL Science Communication Curriculum Cohort 1
- BEHAVIORAL Science communication curriculum Cohort 2
- BEHAVIORAL Science communication curriculum Cohort 3
- BEHAVIORAL Science communication curriculum Cohort 4
Study Locations (4)
Illinois
- Rush University - Chicago
- University of Chicago - Chicago
Iowa
- University of Iowa - Iowa City
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,400 participants |
| Start Date | 2024-07-02 |
| Est. Completion | 2029-04-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06417762
The ClinicalTrials.gov registry entry for NCT06417762 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 1,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,208-participant average among 203 other COVID-19 trials with a reported enrollment target (97% lower). The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with COVID-19 appearing as the primary indexed condition, and to 4 interventions - of which Science Communication Curriculum Cohort 1 is the first listed.
NCT06417762 reports 4 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Iowa, Michigan.
Frequently Asked Questions
What is clinical trial NCT06417762 about?
NCT06417762 is a clinical study titled "Dime La VerDAD: Verify, Debunk, and Disseminate". Dime la Verdad (Tell me the truth) will evaluate the use of storytelling by community health workers as a communication strategy to disseminate reliable health information on social media and encourage informed decision-making in favor of recommended immunizations in communities with high morbidity ...
What is the current status of trial NCT06417762?
This trial is currently recruiting. It is a NA study. The enrollment target is 1,400 participants. The study started on 2024-07-02. Estimated completion is 2029-04-01.
What conditions does trial NCT06417762 study?
This clinical trial studies the following conditions: COVID-19, Influenza, Health Behavior, Communication Research, Respiratory Viral Infection.
What interventions are being tested in trial NCT06417762?
The interventions under investigation include: Science Communication Curriculum Cohort 1 (BEHAVIORAL), Science communication curriculum Cohort 2 (BEHAVIORAL), Science communication curriculum Cohort 3 (BEHAVIORAL), Science communication curriculum Cohort 4 (BEHAVIORAL).
Who is sponsoring clinical trial NCT06417762?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06417762 being conducted?
This trial has 4 study locations across Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19
RECRUITING · NA
-
Music Mindfulness Study 2a.
RECRUITING · NA
-
Percutaneous Electrical Nerve Field Stimulation (PENFS) in Patients With Post Concussion Syndrome (PCS)
RECRUITING · NA
-
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
RECRUITING · NA
-
Evaluating the Impact of Social Music
RECRUITING · NA
-
The SINCERE Intervention to Address COVID-19 Health Disparities
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.